Euro
USD
British Pound
NULL
Product Description
PARK2 Antibody | 7903 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: PARK2 antibody was raised against a 17 amino acid peptide near the amino terminus of human PARK2.
The immunogen is located within amino acids 110 - 160 of PARK2.
Research Area: Neuroscience, Apoptosis
Tested Application: E, WB, IHC-P, IF
Application: PARK2 antibody can be used for detection of PARK2 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Specificiy: PARK2 antibody is human specific.
Positive Control 1: Cat. No. 1362 - Human Cerebellum Tissue Lysate
Positive Control 2: Cat. No. 10-301 - Human Brain Tissue Slide
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Predicted: 51 kDa
Observed: 55 kDa
Validation: N/A
Isoform: N/A
Purification: PARK2 antibody is affinity chromatography purified via peptide column.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PARK2 antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: PARK2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Alternate Name: PARK2 Antibody: PDJ, PRKN, AR-JP, LPRS2, E3 ubiquitin-protein ligase parkin, Parkinson juvenile disease protein 2, Parkinson disease protein 2
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Parkinson’s disease (PD) is a neurodegenerative disease whose symptoms include tremors, rigidity, bradykinesia, and postural instability (1) . Mutations in the PARK2 gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease (2) . The PARK2 protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation (3) . Recent studies have suggested that PARK2 expression reduces the mitochondrial accumulation of the apoptosis protein Bax under basal conditions and directly ubiquitinates Bax, thereby promoting cell survival (4) .
